This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent
A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.
⬅ Back home Read full article ➡